Targeting CMTM6 restores EGFR degradation, suppresses tumor growth, and confers therapeutic benefit in both CDX and PDX models, offering a promising strategy against TKI‐resistant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.